Real-world outcomes with avelumab + axitinib in patients with advanced renal cell carcinoma in Japan: subgroup analyses from the J-DART2 study by International Metastatic Renal Cell Carcinoma Database Consortium risk classification
International Journal of Clinical Oncology · 2025
DOI: 10.1007/s10147-024-02655-4 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Clinical Oncology, 2025. Verfasst von Junya Furukawa und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-Cho, Chuo-ku, Kobe, 650-0017, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Axitinib, Kidney Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck KGaA, Pfizer.
Abstract (Originalsprache)
Background
Avelumab + axitinib was approved for the treatment of advanced renal cell carcinoma (aRCC) in Japan in December 2019. We report long-term real-world subgroup analyses with first-line avelumab + axitinib in patients with aRCC by International Metastatic RCC Database Consortium (IMDC) risk classification from the J-DART2 study in Japan.
Methods
J-DART2 was a multicenter, noninterventional, retrospective study examining characteristics, treatment patterns, and outcomes in patients with aRCC who started first-line avelumab + axitinib in Japan between December 2019 and October 2022.
Results
Data from 150 patients across 19 sites were analyzed. IMDC risk was favorable in 39 patients (26.0%), intermediate (1 risk factor) in 46 (30.7%), intermediate (2 risk factors) in 36 (24.0%), and poor in 29 (19.3%). Baseline characteristics were generally consistent across IMDC risk subgroups. In subgroups with favorable, intermediate (1 risk factor), intermediate (2 risk factors), and poor risk, median progression-free survival was 31.0, 15.3, 16.4, and 8.1 months; median overall survival (OS) was not reached, but 24-month OS rates were 95.2%, 91.3%, 85.3%, and 57.6%, respectively. Objective response rates were 54.5%, 56.8%, 47.1%, and 54.2%, respectively. High-dose corticosteroid treatment for immune-related adverse events was administered in 5.1%, 8.7%, 8.3%, and 6.9% of patients, respectively.
Conclusion
Subgroup analyses from J-DART2 confirm the long-term real-world effectiveness of first-line avelumab + axitinib across IMDC risk groups in patients with aRCC in Japan. Our findings were consistent with previous analyses by IMDC risk and support the favorable benefit-risk profile of avelumab + axitinib in clinical practice in Japan.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-Cho, Chuo-ku, Kobe, 650-0017, Japan.
- Department of Urology, Tokushima University, Graduate School of Biomedical Sciences, 3-18-15 Kuramoto-cho, Tokushima, 770-8503, Japan.
- Department of Urology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
- Department of Urology, Kobe City Medical Center General Hospital, 2-1-1 Minatojima Minamimachi, Chuo-ku, Kobe, 650-0047, Japan.
- Department of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
- Department of Urology, Sapporo Medical University School of Medicine, South-1, West-16, Chuo-ku, Sapporo, Hokkaido, 060-8543, Japan.
Förderung
- Merck KGaA
- Pfizer
Zitieren
APA
Furukawa, J., Kato, T., Yamasaki, T., Monji, K., Tanaka, T., Tsuchiya, N., Miyagawa, T., Yaegashi, H., Sano, T., Karashima, T., Fujita, K., Hori, J. I., Ito, T., Kajita, M., Tomita, Y., Shinohara, N., Eto, M., Oya, M., & Uemura, H. (2025). Real-world outcomes with avelumab + axitinib in patients with advanced renal cell carcinoma in Japan: subgroup analyses from the J-DART2 study by International Metastatic Renal Cell Carcinoma Database Consortium risk classification. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-024-02655-4
Vancouver
Furukawa J, Kato T, Yamasaki T, Monji K, Tanaka T, Tsuchiya N, et al. Real-world outcomes with avelumab + axitinib in patients with advanced renal cell carcinoma in Japan: subgroup analyses from the J-DART2 study by International Metastatic Renal Cell Carcinoma Database Consortium risk classification. International Journal of Clinical Oncology. 2025. doi:10.1007/s10147-024-02655-4
BibTeX
@article{Furukawa2025,
author = {Furukawa, Junya and Kato, Taigo and Yamasaki, Toshinari and Monji, Keisuke and Tanaka, Toshiaki and Tsuchiya, Norihiko and Miyagawa, Tomoaki and Yaegashi, Hiroshi and Sano, Tomoyasu and Karashima, Takashi and Fujita, Kazutoshi and Hori, Jun-Ichi and Ito, Takayuki and Kajita, Masahiro and Tomita, Yoshihiko and Shinohara, Nobuo and Eto, Masatoshi and Oya, Mototsugu and Uemura, Hirotsugu},
title = {Real-world outcomes with avelumab + axitinib in patients with advanced renal cell carcinoma in Japan: subgroup analyses from the J-DART2 study by International Metastatic Renal Cell Carcinoma Database Consortium risk classification},
journal = {International Journal of Clinical Oncology},
year = {2025},
doi = {10.1007/s10147-024-02655-4}
}
EUVIMED